Uncategorized
FDA commissioner calls for public input on lifting generic barriers
In introducing the FDA’s Drug Competition Action Plan, the commissioner announced his intent to assess ways FDA rules may be misused to create obstacles against generic drug access and competition; the organization plans to hold a meeting on July 18, 2017, to solicit input from the public.“Too many patients are being priced out of the medicines they need,” Scott Gottlieb, MD, commissioner of the FDA, wrote in the FDA’s blog. “While FDA doesn’t have a direct role in drug pricing, we can take steps to help address this problem by (Read more...)